Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT05996952
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05980481
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
- Conditions
- Non-Muscle Invasive Bladder CancerHER2
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05957757
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05940896
- Locations
- 🇨🇳
Shandong Cancer hospital &Institute, Jinan, Shandong, China
Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation
- Conditions
- Urothelial Carcinoma
- Interventions
- Radiation: radiotherapy
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT05912205
Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients
- Conditions
- Upper Urinary Tract Urothelial CarcinomaKidney PreservationPD-1antibodyHER-2 ADC
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05912816
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 400
- Registration Number
- NCT05911295
- Locations
- 🇺🇸
Foothill Cardioology, Arcadia, California, United States
🇺🇸Beverly Hills Multi-Specialties Practice, Beverly Hills, California, United States
🇦🇷Hospital Municipal de Morón. O. B. Lavignolle, Morón, Argentina
Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
- Conditions
- HR Positive/HER2 Low Expression Metastatic Breast Cancer
- Interventions
- Other: Endocrine therapy
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-22
- Target Recruit Count
- 288
- Registration Number
- NCT05904964
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Hainan Qionghai People's Hospital, Qionghai, Hainan, China
🇨🇳The Second Affiliated Hospital， Shantou University Medical College, Shantou, Guangdong, China
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
- Conditions
- Salivary Gland Cancer
- Interventions
- Drug: vedicitumomab (Edisil, RC48）Drug: vedicitumomab in combination with pyrrolizidine
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 120
- Registration Number
- NCT05898373
RC48-ADC in Breast Cancer
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05851677
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.